Guggenheim analyst Steven Forbes assumes Overstock.com (NASDAQ:OSTK) with a Neutral rating.
Analyst Downgrades FibroGen On Questions Regarding Future Direction
Earlier today, FibroGen Inc (NASDAQ: FGEN) said its Phase 3 ZEPHYRUS-1 trial of pamrevlumab in idiopathic pulmonary fibrosis (IPF) did not meet the primary endpoint of change in forced vital capacity (FVC) from baseline at week 48 or the secondary endpoint of a decline in FVC percent
